AlphaVax

AlphaVax is a North Carolina-based biotechnology company specializing in the development of innovative vaccines. Headquartered in Durham, AlphaVax employs a team of 9 dedicated professionals focused on advancing groundbreaking vaccine technologies. AlphaVax's pipeline is focused on addressing critical public health challenges. Their primary targets include pandemic influenza and cytomegalovirus (CMV), while grant and collaborative research extends to programs addressing HIV, prostate and breast cancers, and biodefense threats. The company's research has yielded promising results, with clinical data from initial human trials demonstrating the safety and efficacy of their alphavaccine platform. This platform generates robust and balanced antibody and cellular immune responses, offering a strong foundation for future vaccine development. For more information about AlphaVax and their innovative vaccine solutions, please visit www.alphavax.com.